利特昔替尼治疗斑秃的临床应答模式:ALLEGRO项目分析
该事后分析评估了191例接受利特昔替尼50 mg治疗的斑秃患者(≥12岁,头皮脱发≥50%)的SALT评分轨迹至第24个月。45.5%为应答者(SALT≤20),其中93.1%维持应答,46.0%达到完全缓解;女性、脱发范围较小和病程较短与治疗应答相关。
要点
- 约45%患者SALT≤20,其中93.1%维持应答,46.0%达完全缓解。
- 最高11%患者需超过1年治疗才达到应答,提示延长疗程的重要性。
- 女性、脱发范围较小和病程较短与治疗应答相关。
核心结论
- 约45%患者为SALT评分应答者,其中93.1%维持应答,46.0%达到完全缓解。
- 最高11%患者需超过1年利特昔替尼治疗才达到应答,强调延长治疗时长的重要性。
研究设计与样本
- 事后分析评估从2b/3期研究滚动进入ALLEGRO-LT研究的患者,接受利特昔替尼50 mg每日一次。
- 纳入年龄≥12岁、头皮脱发≥50%的患者,共191例接受利特昔替尼50 mg治疗。
- 按SALT评分轨迹至第24个月分类为早期、中期、晚期应答者或部分应答者、复发者、无应答者。
主要发现
- 191例中87例(45.5%)为应答者(SALT≤20),24例(12.6%)为部分应答者,24例(12.6%)为复发者,56例(29.3%)为无应答者。
- 87例应答者中81例(93.1%)维持临床应答,47例(46.0%)达到完全缓解(SALT=0至少1次)。
- 与治疗应答相关的因素包括女性、脱发范围较小和脱发病程较短。
关键数值与推荐
- 应答者定义为SALT评分≤20;部分应答者维持30%改善;复发者达到但未维持30%改善;无应答者未达到30%改善。
- 持续应答定义为达到并维持SALT≤20至第24个月所有后续可用时间点;完全缓解定义为至第24个月至少1次SALT=0。
临床怎么用
- 利特昔替尼50 mg治疗斑秃约45%患者可达SALT≤20,多数应答者可维持应答。
- 部分患者需超过1年治疗才达到应答,临床应延长治疗时长以评估疗效。
- 女性、脱发范围较小和病程较短的患者更可能对治疗应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, demonstrated efficacy over 48 weeks in patients with alopecia areata (AA) in the ALLEGRO phase 2b/3 study. OBJECTIVES: This post hoc analysis evaluated individual Severity of Alopecia Tool (SALT) score trajectories in patients who received ritlecitinib 50 mg and rolled over from Phase 2b/3 into the ongoing, open-label, Phase 3 ALLEGRO-LT study to describe long-term response patterns and associated baseline disease characteristics. METHODS: Patients aged ≥12 years with ≥50% scalp hair loss received ritlecitinib 50 mg once daily in both studies. SALT score trajectories from baseline to Month 24 were used to categorise patients as early (SALT score ≤20 at Week 24 and Months 12 and 24), middle (≤20 at Months 12 and 24) or late responders (≤20 by Month 24) or as partial responders (maintained 30% improvement), relapsers (achieved but did not maintain 30% improvement) or non-responders (did not achieve 30% improvement). The proportions of patients achieving sustained response (achieved and maintained SALT score ≤20 at all subsequent available time points through Month 24) and complete response (SALT score 0 at ≥1 time point through Month 24) were evaluated. Multivariable logistic regression assessed variables associated with response. RESULTS: Of 191 patients treated with ritlecitinib 50 mg, 87 (45.5%) were responders (SALT score ≤20), 24 (12.6%) were partial responders, 24 (12.6%) were relapsers and 56 (29.3%) were non-responders. Of 87 patients categorised as responders, 81 (93.1%) sustained their clinical response and 47 (46.0%) achieved complete response. Factors associated with treatment response included female sex and less extensive and shorter duration of hair loss. CONCLUSIONS: Approximately 45% of patients were SALT score responders, with up to 11% requiring >1 year of ritlecitinib treatment to achieve response, highlighting the importance of extended treatment duration. GOV REGISTRATION: ALLEGRO phase 2b/3 study (NCT03732807); ALLEGRO-LT study (NCT04006457).
引用
- King B, Mirmirani P, Lo Sicco K, et al. Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme. J Eur Acad Dermatol Venereol. 2025. PMID: 39962358. doi:10.1111/jdv.20547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。